HumanKine® recombinant human IL-34 protein

Purity of recombinant human IL-34 was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue

Recombinant IL-34 (HZ-1316) stimulates dose-dependent proliferation of PBMCs. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. PBMCs were treated with increasing concentrations of IL-34 for 6 days. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 2-12 ng/mL.

Proteintech IL-34 (HZ-1316) demonstrates a 2-fold decrease in EC50 and equivalent fold induction compared to leading competitors. Recombinant IL-34 stimulates dose-dependent proliferation of PBMCs. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. PBMCs were treated with increasing concentrations of IL-34 for 6 days. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 2-12 ng/mL.

Human PBMC cells were seeded at a density of 100,000 cells per well in a non-tissue culture treated ​96-well plate. Cells were cultured in RPMI1640 + 10% FBS treated 100 ng/mL of Proteintech recombinant IL-34 (HZ-1316) for 6 days.

1 million THP-1 cells were seeded in a 24-well plate with serum free RPMI 1640 medium overnight. ​ Cells were treated with indicated amounts of IL-34 (HZ-1316) for 5 min before lysis with RIPA buffer. ​ Phosphorylation ERK 1/2 (PTG #28733-1-AP) and total ERK 1/2 (PTG #11257-1-AP) antibodies were​ used to detect IL-34 induced ERK1/2 phosphorylation.